{
  "openalex_id": "W4392384100",
  "doi": "https://doi.org/10.7326/j24-0004",
  "title": "In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo",
  "abstract": "ACP Journal Club5 March 2024In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 moAhmad Masri, MD, MS, Harriette G.C. Van Spall, MD, MPHAhmad Masri, MD, MSOregon Health & Science University, Portland, Oregon, USA (A.M.), Harriette G.C. Van Spall, MD, MPHMcMaster University, Hamilton, Ontario, Canada (H.G.V.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/J24-0004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationMaurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553-1565. https://pubmed.ncbi.nlm.nih.gov/37888916Clinical Impact RatingsGIM/FP/GP: Cardiology: References1. Food and Drug Administration. FDA briefing document: sNDA/015. Drug name: patisiran. Applicant: Alnylam Pharmaceuticals, Inc. Cardiovascular and Renal Products Advisory Committee meeting: 09/13/2023. Accessed at www.fda.gov/media/171977/download on 1 Dec 2023. [PMID: 210922] Google Scholar2. Maurer MS, Schwartz JH, Gundapaneni B, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007-1016. [PMID: 30145929] Google Scholar3. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431-443. [PMID: 30586695] Google Scholar4. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [clinical trial]. Accessed at www.clinicaltrials.gov/study/NCT04153149 on 7 Dec 2023. Google Scholar Author, Article, and Disclosure InformationAuthors: Ahmad Masri, MD, MS; Harriette G.C. Van Spall, MD, MPHAffiliations: Oregon Health & Science University, Portland, Oregon, USA (A.M.)McMaster University, Hamilton, Ontario, Canada (H.G.V.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J24-0004.This article was published at Annals.org on 5 March 2024.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics LatestKeywordsAmyloidosisCardiomyopathiesHazard ratioHeart failureHospitalizationsMortalityPatientsSubgroup analysisWalking ePublished: 5 March 2024 Copyright & PermissionsCopyright Â© 2024 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...",
  "authors": [
    {
      "display_name": "Ahmad Masri",
      "id": "A5065594480",
      "orcid": "https://orcid.org/0000-0002-6390-6526",
      "institutions": [
        {
          "id": "I165690674",
          "display_name": "Oregon Health & Science University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Ahmad Masri"
    },
    {
      "display_name": "Harriette G.C. Van Spall",
      "id": "A5059416021",
      "orcid": "https://orcid.org/0000-0002-8370-4569",
      "institutions": [
        {
          "id": "I98251732",
          "display_name": "McMaster University",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Harriette G.C. Van Spall"
    }
  ],
  "publication_year": 2024,
  "publication_date": "2024-03-01",
  "type": "letter",
  "cited_by_count": 1,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S119722071",
    "display_name": "Annals of Internal Medicine",
    "issn_l": "0003-4819",
    "issn": [
      "0003-4819",
      "1539-3704"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310316812"
  },
  "volume": "177",
  "issue": "3",
  "first_page": "JC30",
  "last_page": "JC30",
  "open_access": {
    "is_oa": false,
    "oa_status": "closed",
    "oa_url": null,
    "any_repository_has_fulltext": false
  },
  "concepts": [
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.9153062
    },
    {
      "id": "C2777607188",
      "display_name": "Cardiac amyloidosis",
      "level": 3,
      "score": 0.7657217
    },
    {
      "id": "C121157162",
      "display_name": "Transthyretin",
      "level": 2,
      "score": 0.74870396
    },
    {
      "id": "C2779951007",
      "display_name": "Amyloidosis",
      "level": 2,
      "score": 0.69196284
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.4662693
    },
    {
      "id": "C74909509",
      "display_name": "Gerontology",
      "level": 1,
      "score": 0.3865495
    },
    {
      "id": "C187212893",
      "display_name": "Pediatrics",
      "level": 1,
      "score": 0.36590087
    },
    {
      "id": "C164705383",
      "display_name": "Cardiology",
      "level": 1,
      "score": 0.34869564
    }
  ],
  "topics": [
    {
      "id": "T11305",
      "display_name": "Amyloidosis: Diagnosis, Treatment, Outcomes",
      "score": 0.9964
    },
    {
      "id": "T10516",
      "display_name": "Parathyroid Disorders and Treatments",
      "score": 0.9652
    },
    {
      "id": "T10821",
      "display_name": "Cardiovascular Function and Risk Factors",
      "score": 0.9576
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.7326/j24-0004",
  "pdf_url": null,
  "retrieved_date": "2025-07-30T15:54:24.622676",
  "source_database": "OpenAlex"
}